A B ST R A CT In an effort to elucidate the nature of the collagen-platelet interaction, the effects of collagen modification on platelet aggregation have been studied. We have shown that purified rat skin (salt) soluble collagen is effective at about 20 nM in mediating platelet aggregation in human platelet-rich plasma. This conce-ntration is somewhat greater than that required of several skin insoluble collagens (ca. 10 nM). Both the al(I) and a2 chains from rat skin soluble collagen produced platelet aggregation, but only at concentrations of about 13 AM and 55 AM, respectively. In contrast, heat-denatured collagen and chains (e.g., 65 AM al(I) and 160 AM a2) failed to induce platelet aggregation and to inhibit platelet aggregation by native collagen.
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Glycopeptides were prepared from human skin insoluble collagen by extended digestion with bacterial collagenase and trypsin, and were purified by gel filtration into two classes. One class of higher molecular weight contained sialic acid, glucosamine, galactosamine, fucose, mannose, galactose, and glucose, and the other of lower molecular weight consisted primarily of a mixture of galactose and galactosyl-glucose units O-glycosidically linked to hydroxylysine-containing peptides. We found that, after the residual tryptic activity contaminating the higher molecular weight fraction was inhibited, neither of the glycopeptide classes produced nor inhibited native human skin insoluble collagen-mediated platelet aggregation at the highest concentration examined (ca. 1-2 mg glycopeptide per ml of platelet-rich plasma). Received for publication 27 November 1972 and in revised form 1 June 1973. glucose (Hyl-Gal and Hyl-Gal-Glc, respectively), were prepared from human urine and labeled at galactose using galactose oxidase followed by reduction with tritiated borohydride. Binding studies with platelet-rich plasnma showed that, at concentrations greater than 50 nM, Hyl-Gal gives apparent binding to platelets, but there was no evidence of Hyl-Gal-Glc binding to platelets at concentrations up to 250 nM. At concentrations several hundredfold higher than the equivalents present in the minimum concentration of rat skin soluble collagen required for platelet aggregation, neither Hyl-Gal (at 29 iM) nor Hyl-Gal-Glc (at 18 AM) caused platelet aggregation or inhibited platelet aggregation by native collagen. Also, at a concentration of 85 ,M (which represents a concentration about two thousandfold higher than the equivalents in the minimum concentration of soluble collagen required for platelet aggregation) the Gal-Glccontaining 36 residue rat skin soluble collagen al(I)-cyanogen bromide #5 peptide had no platelet aggregating or inhibiting activity.
Modification of at least 90% of the rat skin soluble collagen carbohydrate by mild periodate oxidation had no effect on the platelet aggregating activity. Human skin insoluble collagen was reacted with periodate under the same conditions, and this had no demonstrable effect on its ability to induce platelet aggregation. This indicates that the normal carbohydrate side chains of these collagens are not required for the platelet interaction that produces the release of ADP and other metabolic constituents and leads to aggregation.
Thus, collagen-platelet interactions appear to involve at least two distinct binding sites on the platelet plasma membrane. One is a protein binding site that activates platelet aggregation and has high specificity and affinity for the collagen triple-helical fold or perhaps even for a particular amino acid sequence in the triple helix. (1) (2) (3) (4) (5) (6) ). This binding is followed by the release of ADP, 5-hydroxytryptamine, and other substances from the bound platelets, thus causing additional circulating platelets to adhere to the original deposition. These aggregating platelets undergo rather dramatic morphological changes (7, 8) and in the presence of thrombin rapidly fuse to form a "hemostatic plug." Hence, platelet aggregation is the first step in hemostasis; fibrin formation is initiated only after this has occurred.
Clearly, an understanding of the nature of the initial binding event is of both clinical and basic biochemical interest. For example, the elucidation of this normal physiological mechanism involving a macromoleculecell interaction may provide a rigid framework for the design of specific therapeutic agents that inhibit platelet aggregation and, thus, would be of potential use in preventing or perhaps disrupting arterial thromboses. Recent evidence indicates that collagen is the connective tissue component to which platelets adhere (9) (10) (11) (12) . It was initially shown by Butler and Cunningham (13, 14) that soluble collagen contains only galactose and galactosyl-glucose units O-glycosidically linked to the hydroxyl group of hydroxylysine. The insoluble collagen fraction was later shown by Cunningham and Ford (15) (16) (17) (18) has led to the proposal (18) (19) (20) that the collagen carbohydrate sidechain represents the "recognition site" and that the binding involves an enzyme-substrate (or inhibitor) type interaction, e.g., platelet-glucosyltransferase complexed with collagen-gal. This hypothesis is a specific example of Roseman's (21) generalized theory regarding intercellular interactions and Cunningham's (22) suggestions pertinent to the role of glycoproteins in cellular recognition.
The purpose of this work is to examine the nature of the platelet-collagen interaction using well characterized collagen samples and collagen derivatives. Specifically, we are interested in determining if both the normal collagen carbohydrate and the triple helical structure are necessary for this interaction or if it is mediated mainly through the protein moiety. Collagen extraction and purification. RSSC' was obtained from lathyritic male Sprague-Dawley rats using the method of Bornstein and Piez (23) . Guinea pig skin (salt, acid, and citrate) soluble collagen was prepared as described elsewhere (14) , and bovine skin (acid) soluble collagen was kindly given to us by Dr. Edward J. Miller. Human infant skin (acid) soluble collagen was prepared by extraction with 0.5 M acetic acid, followed by dialysis against 10 mM Na2HPO4 to precipitate the collagen fibrils.
METHODS
The rat, human, and guinea pig insoluble skin collagens were prepared by the method of Veis et al. (24) , as modified by Cunningham and Ford (15) . The human insoluble tendon collagen was isolated and purified using the method of Segrest and Cunningham (25) . The chick sternal cartilage and the bovine articular cartilage (pepsin solubilized) collagens were kindly provided by Dr. Edward J. Miller (26, 27) .
Preparation of platelet-rich plasma. Whole blood was obtained from healthy adults who were not taking oral contraceptives and had not ingested acetylsalicylic acid for at least 7 days. Blood (10-90 ml) was collected using an 18 gauge needle and sterile plastic syringes containing sodium citrate as an anticoagulant (1: 9, 3.2% sodium citrate: blood). The blood was transferred to plastic centrifuge tubes, and the white cells and erythrocytes were removed by centrifugation for 8-16 min at 180 g using the Sorvall were used within 3-4 h for the binding and aggregation studies. Platelet concentration was determined using a Coulter Counter, and these were always in the normal range, ca 300,000 platelets per mm3. The material remaining from the original centrifugation was centrifuged for 8 min at 37,000 g (Sorvall RC2-B, SS-34 rotor) to separate the cells from the PPP. All of the above operations were conducted at room temperature.
Isolation and tritiation of thc hydro.xylysyl glycosides. The highly purified hydroxylysyl glycosides, Hyl-Gal and Hyl-Gal-Glc, were isolated from human urine as described earlier (25, 28) . These compounds were tritiated at C-6 of galactose, using purified galactose oxidase (29) (28) . The tritiated Hyl-Gal fraction was pooled, lyophilized, and desalted using the Bio-Gel P-2 column.
Hyl-Gal-Glc was labeled using co0litions similar to those described for Hyl-Gal. Notable differences included the use of tritiated sodium borohydride, 25 U of galactose oxidase, the addition of 4 Ig of catalase (30) , and incubation for 48 h. The labeled Hyl-Gal-Glc was then chromatographed as described above for Hyl-Gal. Preparation of collagen chains and peptides. HSIC (1 g) was digested with collagenase and trypsin exactly as described elsewhere (15) . After the 2-day digestion, the soluble portion was chromatographed on a 2.5 X 96 cm Sephadex G-25 (coarse) column equilibrated and developed with 0.1 M pyridine-acetate, pH 5. The effluent was monitored both by ninhydrin and orcinol analysis (31) .
The RSSC al (I) and a2 chains, as well as the mixture of CNBr peptides, were generously provided by Dr. Hector Aguilar. The individual chains were prepared according to Piez et al. (32) and Bornstein and Piez (23) . The al(I) chains as prepared by this method are contaminated with some p11 chains; however, we rechromatographed the fraction on CM-cellulose in order to reduce the ,11 contamination. The CNBr peptides were prepared as described by Butler and Ponds (33) . No attempt was made to fractionate these. The highly purified al(I)-CNBr #5 peptide from RSSC was kindly provided by Dr. William T. Butler.
Preparation of carbohydrate-modified collagen. The carbohydrate moieties of RSSC were modified by periodate oxidation, using essentially the conditions specified by Spiro (34) for renal glomerular basement membrane. RSSC was dissolved in 0.9%o NaCl or water to give a solution of 2 mg/ml. The solution was then made 50 mM in sodium acetate buffer, pH 4.5, and a concentrated solution of sodium mn-periodate in saline was added to give a final concentration of 24 mM (the final protein concentration was about 90% of the original value). The incubation flask was wrapped in aluminum foil, and incubation proceeded for 25-27 h with occasional stirring. The reaction was terminated by the addition of excess ethylene glycol, although platelet aggregation experiments were conducted both before and after the addition of ethylene glycol. A collagen control was always prepared in which saline was added in place of periodate. All of the above steps were at 50C, and all solutions were maintained in the dark until addition to the PRP in the aggregometer. Before chemical analysis the mixture was dialyzed against distilled water and lyophilized. A limited amount of HSIC was also reacted under identical conditions. HSIC was first homogenized (Thomas-B37429 homogenizer), then stirred for several hours and finally centrifuged for 5 min at 180 y. The supernate was then used in the periodate oxidation.
RSSC was incubated with galactose oxidase, using a modification of the conditions reported by Spiro (30) for renal glomerular basement membrane RSSC was dissolved in either distilled water or 0.9% NaCl at 50C to a final concentration of 2 mg/ml. The solution was then made 50 niM in sodium phosphate buffer, pH 6.8+0.2, followed by the addition of lyophilized galactose oxidase (0.1 mg enzyme per mg collagen) and catalase (1 mg enzyme per 300 mg collagen). Originally, the incubation was for 24-27 h at 30°-35°C; however, this resulted in pronounced aggregation, i.e., visible clumps, such that the collagen could be centrifuged out at low speed. We also performed the incubation for 7 h at 25°C, and whereas this resulted in some opalescence, clarification of the solution was readily effected by lowering the pH to 4.64.8. Occasionally, excess sodium borohydride was added to the mixture and incubated for 45 min before the pH was lowered.
Collagen-mediated platelet aggrcgation. Aggregation studies were performed with 1 ml of PRP (stirring at 900 rpm) at 37°C using the Peyton Aggregation Module (Peyton Associates, Inc., Buffalo, N. Y.) with a Bausch and Lomb Inc. 10 mV VOM-5 recorder. The instrument was adjusted for 100% transmission with 1 ml of PPP and for 0% transmission with 1 ml of PRP. Generally, collagen (or collagen derivatives) was added in a volume of 50 ul, although occasionally volumes of 5-100 ,l were used. The transmittance of the samples was followed with time and displayed on the recorder (ca. 4 inches full scale and a chart speed of 1 inch/min). Aggregation invariably registered 100% transmission, and particulate formation was always confirmed by visual observation.
Binding of labeled hydroxylysyl glycosides to platelets.
The binding studies were performed with 1 ml of PRP and various concentrations of hydroxylysyl glycosides in buffer at a volume of 100 Al. Controls of PPP were present for every sample. The samples and controls were incubated for 30 min at 370C with occasional stirring. These were then centrifuged for 50 min (5°C at 12,350 g), and aliquots of the supernates were diluted with Aquasol and counted in a Packard Liquid Scintillation Spectrometer.
Carbohydrate and amino acid analysis. Neutral sugars were qualitatively analyzed as the alditol-acetate derivatives using the GLC method of Lehnhardt and Winzler (35) , sometimes with slight modifications. For example, hydrolysis was occasionally performed in 2 N HCl for 4 h, at 100°C. Arabinose was then added as an internal standard, and the sample was dried on a rotary evaporator. The residue was dissolved in water and applied to the standard ion exchange tandem columns (35) .
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Total neutral sugars of the HSIC collagenase-trypsin glycopeptides were determined using the automated orcinol method described elsewhere (31) . Total sialic acid of these glycopeptides was analyzed using established method (36, 37) . Glucosamine was measured on the 15 cm column of the amino acid analyzer after hydrolysis (in evacuated ampoules) in 4 N HCl for 6 h at 1100C.
Glucose and galactose of RSSC and carbohydrate-modified RSSC were quantitatively determined using the Glucostat and Galactostat Kits after hydrolysis and ion exchange chromatography as described above. The amounts of glucose and galactose in RSSC were measured using 145 and 68 mg of collagen, respectively. These levels permitted three different concentration determinations for each carbohydrate.
Amino acid analysis of the glycopeptides was performed on a Beckman 120 Amino Acid Analyzer after hydrolysis (in evacuated ampoules) in 6 N HCl for 20 h at 1100C (38) . Hydroxyproline was determined on a separate run at 300C.
The protein concentrations of the soluble collagens were determined from dry weight measurements on the lyophilized, salt-free powder. Concentrations of the insoluble collagens were estimated using the micro-Biuret method (39) on the supernates after homogenization and centrifugation (180 g); RSSC and chick sternal cartilage collagen were used as standards. RESULTS
Collagen-mnediated platelet aggregation. In order to achieve optimum reproducibility in the platelet aggregations, particular care was taken to ensure that no large collagen particules were present. For and II are given in Table I . The first glycopeptide peak to elute, i.e., pool I, contains glucosamine, fucose, sialic acid, mannose, galactose, glucose, and trace amounts of galactosamine, whereas the second hexose positive peak, i.e., pool II, contains mainly galactose and glucose (some carry-over of pool I into pool II is indicated by the presence of glucosamine in the latter). The large ninhydrin-positive peak represents amino acids and small peptides. Each of the major peaks shown in Fig. 1 is known to be heterogeneous (15) .
Pools I and II were dissolved in 0.9% and checked for platelet aggregation and inhibition. It was found that at levels of 10 ug to 1.0 mg, pool I neither aggregated platelets nor inhibited aggregation by HSIC. The latter studies were conducted after incubation of PRP with pool I for 5 min at 37"C; in fact, there was no effect of pool I on the lag time after addition of HSIC. Fig. 2 Pool II (4 Pg to 2 mg) neither aggregated platelets nor inhibited their aggregation by HSIC as shown in Fig. 2b for 1 .0 mg of pool II. Likewise, 2 mg of the large ninhydrin positive peak in Fig. 1 had no effect on platelet aggregation. As shown in Fig. 2 , pools I and II did not produce aggregation during the 5 min incubation; other experiments (data not presented) confirmed there was no aggregation even after 30 min incubation.
Effects of collagen modification-alteration of the carbohydrate moiety. Carbohydrate analyses are given in Table II Periodate-oxidized RSSC was found to aggregate platelets in a fashion similar to normal RSSC as shown in some typical aggregation profiles in Fig. 3 a and 3 b. The dependence of the extent of aggregation on RSSC (normal and periodate oxidized) concentration is present in Fig. 4 . It can be seen that within experimental error periodate-oxidized RSSC aggregates platelets with the same effectiveness as unmodified RSSC. This was checked both before and after the addition of ethylene glycol, which alone did not produce platelet aggregation. To obtain maximum solubility, the periodate oxidized RSSC solution was maintained at 50C (in the dark) until addition to the aggregometer. A control was always present under the same conditions( the addition of RSSC at 5PC gave a normal platelet aggregation although the lag times were generally somewhat longer than 250C).
We also reacted HSIC with periodate and found that the product still produced platelet aggregation. It was noted that extended incubations of RSSC with periodate (e.g., several days) yielded a derivative that was much less effective in platelet aggregation. Presumably, this is due to secondary reactions occurring at the protein moiety.
Alteration of the carbohydrate by incubation of RSSC with the galactose oxidase-catalase system of Spiro (30) (30) . In any case, the product is fully active in platelet aggregation.
Studies involving the hydroxylysyl glycosides. The purity of the labeled hydroxylysyl glycosides was established by their Rt on a calibrated Dowex 50 column (28) and by amino acid analysis. The latter was also used quantitatively to determine concentrations. We found that Hyl-Gal (10-29 AM) and Hyl-Gal-Glc 18 iM) failed to produce platelet aggregation. These upper limits represents at least a several hundredfold increase over the amount of carbohydrate present in the minimum level of RSSC required for platelet aggregation. Also, phase microscopy indicated that there was no gross change in platelet morphology; moreover, relative to PRP there was no additional clumping. Spectroscopic measurements were made on the supernates of centrifuged PRP (control, hydroxylysyl glycoside treated and collagen treated); however, no conclusions could be drawn since all three samples gave similar spectra over the wave length interval 240-700 nm. We found that the absorption spectrum (400-700 nm) of PRP was only slightly altered by the addition of the hydroxylysyl glycosides (an apparent decrease in the optical density was also registered on the aggregometer). There appeared to be no inhibition of collagen-mediated aggregation since the subsequent addition of HSIC gave normal aggregation.
Whereas the hydroxylysyl glycosides neither produce platelet aggregation nor inhibit aggregation, it is possible that they bind to platelets. The results of our binding studies using PRP are summarized in Fig. 5 where the extent of binding r, i.e., the number of molecules of hydroxylysyl glycoside bound per platelet, is plotted as a function of the logarithm of the unbound hydroxylysyl glycoside concentration over the range of about 0.2 nM to 9 AM Hyl-Gal and 0.4 nM to 0.25 AM Hyl-Gal-Glc.
The brackets indicate the estimated counting and dilution errors associated with each measurement. We are using the term "binding" in an operational sense, 50 collagen equivalents and about twice that present in the minimum amount of collagen required for aggregation) there is no indication of Hyl-Gal-Glc binding up to 250 nM. Above 250 nm Hyl-Gal-Glc, we obtained an apparent "negative binding," perhaps due to a platelet-dependent fluorescing factor. If so, the extent of Hyl-Gal binding may be even higher. In any case, 250 nM Hyl-Gal-Glc represents about 125 collagen equivalents and roughly six times that present in the minimum collagen concentration necessary for platelet aggregation. Binding studies on washed platelets from outdated platelet concentrates also indicated some binding of Hyl-Gal, thus showing that a serum factor is not required for this interaction. 'Many of the binding studies involving Hyl-Gal were also performed in the presence of UDP-Glc; as can be seen in Fig. 5 , this had no effect on binding.
The solid line in Fig. 5 is theoretical and was plotted according to the equation below. This relationship follows from the law of mass action (42) reported that although neither native bone nor tendon collagen will produce platelet aggregation (19, 43) , other insoluble collagens as well as soluble collagens are effective (10, 12) . Our results clearly demonstrate that purified RSSC and other soluble collagens are effective in extremely small amounts in platelet aggregation. Although even slightly smaller amounts of purified insoluble skin collagens are effective, the use of soluble collagen is preferred for both research and clinical purposes since the reproducibility of measurements is greatly improved and, also, because soluble collagens are chemically better characterized than are insoluble collagens.
The various skin collagens used in this study are of the al (1)2 a2 class (44), whereas the chick cartilage collagen (26, 44) and the bovine articular cartilage collagen (45) are of the al (I)3 class. Interestingly, both classes of collagen are active in platelet aggregation. Platelet aggregation by protein-modified collagen. Purified al (I) and a2 chains (23, 32) are both active in inducing platelet aggregation as also recently shown by Katzman et al. (46) . The finding, however, that relative to native RSSC, large amounts of the individual collagen chains are required for platelet aggregation indicates that there is little intrinsic activity in the separated chains. Also, the difficulty in obtaining purified chains without some contamination by crosslinked chains or partially renatured material is well established (23) , and, thus, some caution is in order regarding these results. Based on the lack of activity in heat-denatured collagen, others have concluded that the collagen-fold is essential for aggregation (12, 47) . We have extended this to show that high concentrations of heat-denatured collagen and a-chains do not inhibit the aggregation caused by native collagen. This indicates that there is little interaction of the heat-denatured material with platelets, at least at the "aggregation" binding sites for native collagen.
Zucker and Borrelli (10) originally reported that purified Clostridium histolyticum collagenase destroyed the ability of both human subcutaneous tissue and mouse tail tendon to aggregate platelets, and later Wilner et al. (12) confirmed that collagenase inactivated the aggregating ability of human skin insoluble collagen. Chesney et al. (47) found that tadpole collagenase inactivated acid-soluble guinea pig skin collagen. This latter enzyme cleaves each of the three collagen chains in nearly the same position producing two triple helical fragments. (48) (49) (50) (51) . On the other hand, Houck and Chang (52) have reported that a rat cutaneous collagenase (53) yields some peptides from RSSC that can produce platelet aggregation.
Our results on the glycopeptide fractions of HSIC after extensive bacterial collagenase and trypsin digestion demonstrate that at the milligram level, these collagen fragments neither aggregate platelets nor inhibit native collagen-mediated platelet aggregation after the residual trypsin activity has been destroyed. In contrast, Jamieson et al. (19) found that a carbohydraterich fraction isolated from a collagenase digest of bovine tendon collagen was able to inhibit collagen aggregation. We found that Hyl-Gal (29 AM) and Hyl-Gal-Glc (18 AM) neither produce nor inhibit the native collagenmediated aggregation of platelets. At high concentrations (e.g., about 20,000 tLM), Katzman et al. (46) demonstrated that Hyl-Gal-Glc inhibits aggregation of platelets by the chick al (I) chains, although Hyl-GalGlc itself did not induce platelet aggregation. The binding sites we found for Hyl-Gal may represent the platelet membrane glycosyltransferases (16, 18, 19) ; however, our data suggest that these do not represent the binding sites which are responsible for platelet aggregation.
Another consideration in evaluating these apparently conflicting results (other than that of the different collagens used) is that collagen microfibrils may enhance platelet aggregation as suggested by Jaffe and Deykin (57) . The carbohydrate moieties of collagen have been implicated in fibril formation (58) , and, conceivably, Collagen-platelet interactions; general considerations.
Our results on platelet aggregation by collagen and various derivatives are summarized in Table III . We have also listed the minimum concentrations (relative to RSSC) required for platelet aggregation activity, or the maximum levels of derivatives we tried which were ineffective. These data show that purified al (I) and a2 chains are much less effective than RSSC, but that heatdenatured collagen and chains, as well as low molecular weight derivatives, are ineffective in producing platelet aggregation even at the highest concentrations we used.
These data, along with the results of Katzman, Kang, and Beachey (46, 55) have led us to develop the tentative scheme, shown schematically in Fig. 6 to summarize our present understanding of collagen-platelet interactions. We propose the presence of at least two distinct sites on the platelet plasma membrane. One is a binding site that leads to platelet aggregation. This site is believed to have high specificity and affinity for the native triple-helical collagen polypeptide moiety or perhaps even for a particular amino-acid sequence in the collagen fold. The affinity of this collagen-platelet interaction is strongly dependent on collagen conformation. As the degree of ordered structure decreases, as in chains or particular peptides, much higher concentrations of the derivatives are required to produce platelet aggregation.
In close proximity to this site is a binding site for carbohydrate units. The platelet receptor in this case may be the glycosyl transferases (16) (17) (18) (19) (20) . The affinity between this site and the collagen carbohydrate is much less than that of the other site and the collagen protein.
Since both the chick skin al (I)-CNBr #5 peptide, which can produce platelet aggregation (46, 55) , and the majority of the carbohydrate are near the aminoterminal region of soluble skin collagen (59, 60) We conclude that under physiological conditions where the criteria of high specificity and affinity are presumably met, the collagen carbohydrate is not a determining factor in collagen binding to platelets, but, rather, the effect is mediated pvrimarily by the native protein moiety.
